Infliximab News and Research

RSS
Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.
Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

DNA methylation identified as potential anti-TNF response biomarker for RA

DNA methylation identified as potential anti-TNF response biomarker for RA

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Adhesion molecule offers promising therapeutic target for preventing colitis

Adhesion molecule offers promising therapeutic target for preventing colitis

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Infliximab drug shows promising results in treating children with Kawasaki Disease

Infliximab drug shows promising results in treating children with Kawasaki Disease

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen launches Inflectra into Central and Eastern Europe

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Study: More people are being affected by drug-induced liver injury than ever before

Study: More people are being affected by drug-induced liver injury than ever before